4 
appreciate your comments on this draft and the transposition 
of prohibited experiments to this section. In light of these 
modifications, your Committee's revisions speaking to "novelty" 
in the prohibitions would be deleted. 
• It was suggested by EMBO that the list of pathogenic organisms 
under the Prohibitions, especially those in Class 5, may not be 
appropriate for all European countries and that such classifi- 
cation should be the responsibility of national or regional 
authorities. Would the Committee object to a footnote here 
stating that the prohibition on etiologic agents relates to 
research in the United States? 
• In response to commentators' suggestions, a statement of general 
applicability, as noted above, would be included in this section. 
On the basis of extensive public comment (discussed more fully 
in the following section on Roles and Responsibilities), it is 
suggested that all institutions receiving any NIH funding for 
recombinant DNA research shall comply with the NIH Guidelines. 
I would appreciate the Committee's views on this recommendation. 
II . Containment 
A. Physical Containment 
There were a large number of public comments urging greater 
detail in the safety practices and procedures. Several commentators 
advised that Appendix D be retained and expanded rather than deleted. 
I fully agree with these suggestions. Accordingly, Dr. W. Emmett 
Barkley has convened a committee that is currently restructuring 
[ 505 ] 
